Akari Therapeutics (AKTX) Price & Analysis

Compare

290 Followers

AKTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.80 - $4.00

Previous CloseN/A

Volume16.29K

Average Volume (3M)39.05K

Market Cap

$28.05M

Enterprise Value$21.25M

Total Cash (Recent Filing)$2.71M

Total Debt (Recent Filing)$1.55M

Price to Earnings (P/E)―

Beta0.53

Next Earnings

Sep 25, 2025

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding32,614,730

10 Day Avg. Volume42,761

30 Day Avg. Volume39,053

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.76

Enterprise Value/Revenue817.46

Enterprise Value/Gross Profit1.63K

Enterprise Value/Ebitda-1.56

Forecast

1Y Price Target

$6.00

Price Target Upside631.71% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst recommendation is a Buy for Akari Therapeutics stock.

Partnership OpportunitiesThe departure from toxin-based payloads, along with validated targets, could make the Akari pipeline attractive for potential partners.

Therapeutic InnovationsPH1-ADCs in preclinical work have demonstrated synergy with checkpoint inhibitors and offer a more favorable toxicity profile, which suggests potential higher therapeutic index.

Bears Say

Capital NeedsThe company is working to address capital needs as it continues to move forward its early-stage antibody drug conjugate (ADC) program.

Akari Therapeutics News

Morning Movers: Under Armour sinks following second quarter earnings

Stock futures are edging higher amid growing expectations that the Federal Reserve may move toward dovish policies, spurred...

21d ago

AMR

Akari Therapeutics reports Q2 EPS (86c) vs. (81c) last year

“In the second quarter of 2025, we continued to build on the strong momentum established with the announcement...

21d ago

AKTX

Akari Therapeutics sees cash runway into 2028

Akero’s cash, cash equivalents and short and long-term marketable securities as of June 30, 2025, were $1,086.2 million....

21d ago

AKTX

Akari Therapeutics Cancels Peak Bio Note and Loan

Akari Therapeutics ( ($AKTX) ) has issued an announcement. Akari Therapeutics has announced a Peak Bio Note and...

8d ago

AKTX

Akari Therapeutics Releases Updated Investor Presentation

An update from Akari Therapeutics ( ($AKTX) ) is now available. On August 19, 2025, Akari Therapeutics, Plc...

10d ago

AKTX

Buy Rating for Akari Therapeutics: Promising ADC Innovations and Growth Potential in Oncology

Jason McCarthy, an analyst from Maxim Group, reiterated the Buy rating on Akari Therapeutics. The associated price target...

14d ago

AKTX

Akari Therapeutics releases ‘What This Means’ segment for investors

Akari Therapeutics (AKTX) announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor...

1M ago

AKTX

Akari Therapeutics reiterates commitment to research on PH1

Akari Therapeutics (AKTX) reiterated its commitment to ongoing research to better understand the multiple effects of its novel...

1M ago

AKTX

Akari Therapeutics ‘just getting started,’ initiated with a Buy at Maxim

Maxim initiated coverage of Akari Therapeutics (AKTX) with a Buy rating and $5 price target The Antibody-Drug Conjugate...

1M ago

AKTX

Akari Therapeutics initiated with a Buy at Maxim

Maxim analyst Jason McCarthy initiated coverage of Akari Therapeutics (AKTX) with a Buy rating and $5 price target...

1M ago

AKTX

Akari Therapeutics Shareholders Approve Key AGM Resolutions

Akari Therapeutics ( ($AKTX) ) has issued an update. On June 30, 2025, Akari Therapeutics held its Annual...

2M ago

AKTX

Akari Therapeutics releases ‘What This Means’ segment for investors

Akari Therapeutics (AKTX) t recently participated in a Virtual Investor “What This Means” segment. For the segment, Abizer...

2M ago

AKTX

Akari Therapeutics announces granting of patent protection in India

Akari Therapeutics (AKTX) announced the Intellectual Property India has issued Patent No. 562,919 titled, “Thailanstatin Analogs”. The issued...

2M ago

AKTX

Akari Therapeutics price target raised to $7 from $4 at Alliance Global

Alliance Global Partners analyst James Molloy raised the firm’s price target on Akari Therapeutics (AKTX) to $7 from...

3M ago

AKTX

AKTX FAQ

What was Akari Therapeutics’s price range in the past 12 months?

Akari Therapeutics lowest stock price was $0.80 and its highest was $4.00 in the past 12 months.

What is Akari Therapeutics’s market cap?

Akari Therapeutics’s market cap is $28.05M.

When is Akari Therapeutics’s upcoming earnings report date?

Akari Therapeutics’s upcoming earnings report date is Sep 25, 2025 which is in 27 days.

How were Akari Therapeutics’s earnings last quarter?

Currently, no data Available

Is Akari Therapeutics overvalued?

According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akari Therapeutics pay dividends?

Akari Therapeutics does not currently pay dividends.

What is Akari Therapeutics’s EPS estimate?

Akari Therapeutics’s EPS estimate is -0.09.

How many shares outstanding does Akari Therapeutics have?

Akari Therapeutics has 32,614,730 shares outstanding.

What happened to Akari Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Akari Therapeutics?

Currently, no hedge funds are holding shares in AKTX

Akari Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-112.22%

Trailing 12-Months

Asset Growth

902.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics (AKTX) Earnings & Revenues

Historic Earnings Reports

AKTX Stock 12 Month Forecast

Average Price Target

$6.00

▲(631.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","12":"$12","24":"$24","36":"$36","48":"$48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,12,24,36,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2021","6":"Dec<br/>2022","9":"Jan<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.01,1.4707692307692308,1.9315384615384614,2.3923076923076922,2.853076923076923,3.3138461538461534,3.7746153846153847,4.235384615384615,4.696153846153846,5.156923076923077,5.617692307692307,6.078461538461538,6.539230769230769,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.01,1.393846153846154,1.7776923076923077,2.161538461538462,2.5453846153846156,2.9292307692307693,3.313076923076923,3.6969230769230768,4.0807692307692305,4.464615384615384,4.848461538461538,5.232307692307692,5.616153846153846,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.01,1.3169230769230769,1.623846153846154,1.930769230769231,2.237692307692308,2.544615384615385,2.851538461538462,3.1584615384615384,3.4653846153846155,3.7723076923076926,4.07923076923077,4.386153846153847,4.693076923076924,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.8,"date":1590969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.8,"date":1596240000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.8,"date":1598918400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.8,"date":1617235200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1625097600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1669852800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >